Can adding selinexor to standard therapy extend remission in Hard-to-Treat myeloma?

NCT ID NCT04939142

Completed Disease control Sponsor: Antengene Corporation Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This phase III trial is testing whether adding selinexor to a standard two-drug regimen (bortezomib and dexamethasone) can help people with relapsed or refractory multiple myeloma—a blood cancer that has returned or stopped responding to treatment. About 154 adults with measurable disease will be randomly assigned to receive either the three-drug combination or the standard two-drug regimen. The main goal is to see if the triple therapy improves progression-free survival, meaning how long patients live without their cancer worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selinexor combined with bortezomib and dexamethasone
What this could lead to: If successful, this combination could offer a new treatment option that helps people with relapsed or refractory multiple myeloma live longer without their cancer progressing.
What could go wrong: This is an early-stage phase III trial, so results are not guaranteed. The addition of selinexor may increase side effects, and the benefit over standard care is still uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Affiliated Hospital of Nantong University

Nanchang, Jiangxi, 330006, China
Beijing Chao-Yang Hospital

Beijing, Beijing Municipality, 100043, China
Guangdong Provincial People'S Hospital

Guangzhou, Guangdong, 510000, China
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China
Nanfang Hospital

Guangzhou, Guangdong, 510515, China
Ningbo First Hospital

Ningbo, Zhejiang, 315010, China
Peking University People'S Hospital

Beijing, Beijing Municipality, 100044, China
Qilu Hospital of Shangdong University

Jinan, Shangdong, 250012, China
Qingdao Municipal Hospital

Qingdao, Shandong, v, China
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 09022836, China
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
Shandong Provincial Hospital

Jinan, Shandong, 250021, China
Shanghai Sixth People's Hospital Affiliated to Shanghai JiaoTong University

Shanghai, Shanghai Municipality, 200233, China
Shengjing Hospital China Medical University

Shenyang, Liaoning, 110004, China
Shenzhen Second People'S Hospital

Shenzhen, Guangdong, 518035, China
Sichuan Provincial People's Hospital

Chengdu, Sichuan, 610072, China
Sir Run Run Shaw Hospital Zhejiang University of Medicine

Hangzhou, Zhejiang, 310016, China
Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266000, China
The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, 221000, China
The First Affiliated Hospital OF USTC

Hefei, Anhui, 230031, China
The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230022, China
The First Affiliated Hospital of Wannan Medical College

Wuhu, Anhui, 241001, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hanzhou, Zhejiang, 310003, China
The First Hospital of Nanchang

Nanchang, Jiangxi, 330006, China
The Third Xiangya Hospital of Central South University

Changsha, Hunan, 410013, China
Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, 300060, China
Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, Hubei, 430030, China
Xiangya Hospital Central South University

Changsha, Hunan, 410008, China
Xinqiao Hospital Army Medical University

Chongqing, Chongqing Municipality, 400037, China
Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.